CG Oncology rises after expediting a late-stage trial readout for lead asset
Source: SeekingAlpha
2026-01-09 13:33:21 ET
More on CG Oncology
- CG Oncology Undervalued Going Into A Busy 2026
- ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves
- ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE
- Seeking Alpha’s Quant Rating on CG Oncology
- Historical earnings data for CG Oncology
Read the full article on Seeking Alpha
For further details see:
CG Oncology rises after expediting a late-stage trial readout for lead asset
CG Oncology, Inc.
NASDAQ: CGON
CGON Trading
1.47% G/L:
$67.48 Last:
1,278,720 Volume:
$65.99 Open:
CGON Latest News
March 21, 2026 06:25:08 pm
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
February 27, 2026 08:30:00 am
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
February 23, 2026 08:00:00 am
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
CGON Stock Data
$4,282,567,443
74,696,882
0.15%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
Irvine
